Amneal Pharmaceuticals, Inc. (AMRX) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
N/A
—
5yr avg: 12.23
30Y Low8.6·High35.7
P/FCF
↑
18.88
↑+123% vs avg
5yr avg: 8.47
30Y Low2.1·High15.9
P/B Ratio
↑
5.46
↓-13% vs avg
5yr avg: 6.28
30Y Low1.3·High17.4
ROE
↑
15.7%
↓+105% vs avg
5yr avg: -296.6%
30Y Low-62%·High26%
Debt/EBITDA
↓
N/A
—
5yr avg: 9.68
30Y Low3.8·High22.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AMRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Amneal Pharmaceuticals, Inc. trades at 73.7x earnings, 17% above its 5-year average of 62.9x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 233%. On a free-cash-flow basis, the stock trades at 18.9x P/FCF, 123% above the 5-year average of 8.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.1B | $4.1B | $2.4B | $1.1B | $300M | $727M | $681M | $637M | $1.7B | $1.9B | $2.5B |
| Enterprise Value | $4.9B | $3.9B | $4.9B | $3.7B | $3.1B | $3.4B | $3.3B | $3.3B | $4.2B | $3.3B | $3.7B |
| P/E Ratio → | 73.68 | 57.27 | — | — | — | 68.43 | 7.49 | — | — | 11.40 | 12.05 |
| P/S Ratio | 1.69 | 1.36 | 0.88 | 0.45 | 0.14 | 0.35 | 0.34 | 0.39 | 1.04 | 1.85 | 2.46 |
| P/B Ratio | 5.46 | 4.24 | — | 17.44 | 1.44 | 1.98 | 1.91 | 1.84 | 1.34 | — | — |
| P/FCF | 18.88 | 15.16 | 11.12 | 3.87 | — | 3.75 | 2.15 | — | 11.24 | 15.95 | — |
| P/OCF | 14.99 | 12.04 | 8.29 | 3.09 | 4.61 | 3.01 | 1.80 | 373.46 | 6.88 | 8.17 | 21.76 |
P/E links to full P/E history page with 30-year chart
AMRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.30 | 1.76 | 1.56 | 1.41 | 1.60 | 1.68 | 2.00 | 2.53 | 3.21 | 3.61 |
| EV / EBITDA | — | — | 10.15 | 8.59 | 21.48 | 8.69 | 10.22 | — | 35.67 | 11.42 | 11.56 |
| EV / EBIT | — | — | 24.21 | 13.74 | 15.60 | 20.01 | 30.29 | — | — | 13.71 | 13.60 |
| EV / FCF | — | 14.58 | 22.40 | 13.49 | — | 17.29 | 10.52 | — | 27.42 | 27.71 | — |
AMRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Amneal Pharmaceuticals, Inc. earns an operating margin of -0.2%. Operating margins have compressed from 8.5% to -0.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 15.7% indicates solid capital efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.9% | 36.9% | 36.5% | 36.1% | 35.8% | 36.7% | 31.5% | 21.7% | 43.1% | 50.9% | 58.7% |
| Operating Margin | -0.2% | -0.2% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% | 23.7% | 28.0% |
| Net Profit Margin | 2.4% | 2.4% | -4.2% | -3.5% | -5.9% | 0.5% | 4.6% | -22.3% | -10.2% | 16.2% | 20.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.7% | 15.7% | -1394.3% | -62.2% | -45.1% | 2.9% | 25.9% | -44.3% | -37.2% | — | — |
| ROA | 2.0% | 2.0% | -3.4% | -2.3% | -3.4% | 0.3% | 2.4% | -9.0% | -6.0% | 13.1% | 18.6% |
| ROIC | -0.2% | -0.2% | 7.3% | 5.3% | -2.4% | 3.8% | 2.3% | -5.5% | -0.6% | 18.1% | 24.3% |
| ROCE | -0.2% | -0.2% | 10.0% | 7.2% | -3.0% | 4.6% | 2.8% | -7.2% | -0.8% | 24.0% | 32.2% |
AMRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $282M exceeds total debt of $124M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | — | 44.87 | 13.62 | 7.84 | 8.41 | 7.99 | 2.09 | — | — |
| Debt / EBITDA | — | — | 5.34 | 6.34 | 19.59 | 7.45 | 9.18 | — | 22.86 | 5.10 | 3.77 |
| Net Debt / Equity | — | -0.16 | — | 43.37 | 13.49 | 7.16 | 7.45 | 7.55 | 1.92 | — | — |
| Net Debt / EBITDA | — | — | 5.11 | 6.13 | 19.41 | 6.81 | 8.14 | — | 21.05 | 4.85 | 3.68 |
| Debt / FCF | — | -0.59 | 11.28 | 9.62 | — | 13.54 | 8.38 | — | 16.18 | 11.76 | — |
| Interest Coverage | — | — | 0.96 | 0.97 | -0.60 | 1.12 | 0.62 | -1.48 | -0.14 | 3.45 | 5.15 |
Net cash position: cash ($282M) exceeds total debt ($124M)
AMRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Amneal Pharmaceuticals, Inc.'s current ratio of 2.17x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.48x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.63x to 2.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 | 2.29 | 2.20 | 2.32 | 2.60 | 3.23 |
| Quick Ratio | 1.48 | 1.48 | 0.86 | 0.94 | 1.17 | 1.52 | 1.57 | 1.51 | 1.50 | 1.64 | 2.04 |
| Cash Ratio | 0.32 | 0.32 | 0.10 | 0.11 | 0.04 | 0.37 | 0.51 | 0.28 | 0.39 | 0.25 | 0.14 |
| Asset Turnover | — | 0.82 | 0.80 | 0.69 | 0.58 | 0.53 | 0.50 | 0.44 | 0.38 | 0.77 | 0.84 |
| Inventory Turnover | 3.14 | 3.14 | 2.90 | 2.63 | 2.68 | 2.71 | 2.78 | 3.34 | 2.07 | 1.79 | 1.58 |
| Days Sales Outstanding | — | 108.23 | 101.34 | 98.46 | 122.39 | 121.12 | 117.05 | 135.64 | 124.08 | 124.07 | 141.52 |
AMRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Amneal Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 10.6% | 19.6% | 8.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | 223.8% | 96.7% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 1.7% | — | — | — | 1.5% | 13.3% | — | — | 8.8% | 8.3% |
| FCF Yield | 5.3% | 6.6% | 9.0% | 25.9% | — | 26.7% | 46.6% | — | 8.9% | 6.3% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 10.6% | 19.6% | 8.0% |
| Shares Outstanding | — | $325M | $309M | $176M | $151M | $152M | $149M | $132M | $127M | $115M | $189M |
Peer Comparison
Compare AMRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AMRXYou | $5B | 73.7 | — | 18.9 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 TEVA | $37B | 26.2 | 16.0 | 31.9 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 VTRS | $18B | -5.1 | 231.2 | 9.2 | 35.1% | -18.6% | -21.1% | -6.6% | 108.7 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 SLDB | $649M | -4.2 | — | — | — | — | -109.9% | -120.8% | — |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 CVS | $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
What is Amneal Pharmaceuticals, Inc.'s P/E ratio?
Amneal Pharmaceuticals, Inc.'s current P/E ratio is 73.7x. The historical average is 34.0x. This places it at the 100th percentile of its historical range.
What is Amneal Pharmaceuticals, Inc.'s ROE?
Amneal Pharmaceuticals, Inc.'s return on equity (ROE) is 15.7%. The historical average is -20.6%.
Is AMRX stock overvalued?
Based on historical data, Amneal Pharmaceuticals, Inc. is trading at a P/E of 73.7x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Amneal Pharmaceuticals, Inc.'s profit margins?
Amneal Pharmaceuticals, Inc. has 36.9% gross margin and -0.2% operating margin.